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Development of a 3D Tissue-Engineered Skeletal Muscle
and Bone Co-culture System
Nicholas M. Wragg,* Diogo Mosqueira, Lia Blokpeol-Ferreras, Andrew Capel,
Darren J. Player, Neil R. W. Martin, Yang Liu, and Mark P. Lewis
In vitro 3D tissue-engineered (TE) structures have been shown to better
represent in vivo tissue morphology and biochemical pathways than
monolayer culture, and are less ethically questionable than animal models.
However, to create systems with even greater relevance, multiple integrated
tissue systems should be recreated in vitro. In the present study, the effects
and conditions most suitable for the co-culture of TE skeletal muscle and
bone are investigated. High-glucose Dulbecco’s modified Eagle medium
(HG-DMEM) supplemented with 20% fetal bovine serum followed by
HG-DMEM with 2% horse serum is found to enable proliferation of both
C2C12 muscle precursor cells and TE85 human osteosarcoma cells, fusion of
C2C12s into myotubes, as well as an upregulation of RUNX2/CBFa1 in TE85s.
Myotube formation is also evident within indirect contact monolayer cultures.
Finally, in 3D co-cultures, TE85 collagen/hydroxyapatite constructs have
significantly greater expression of RUNX2/CBFa1 and osteocalcin/BGLAP in
the presence of collagen-based C2C12 skeletal muscle constructs; however,
fusion within these constructs appears reduced. This work demonstrates the
first report of the simultaneous co-culture and differentiation of 3D TE skeletal
muscle and bone, and represents a significant step toward a full in vitro 3D
musculoskeletal junction model.
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1. Introduction
Currently, in vitro biotoxicity testing of
developmental pharmaceuticals, biomate-
rials, and medical devices is performed
on in vitro monolayer cell culture models
(ISO10993). Monolayer models are capa-
ble of identifying cytotoxic effects through
morphological and biochemical assays or
by assessing changes in gene expression.[1]
However, these results do not effectively
translate across to in vivo tissue systems.[1,2]
This is due to a general failure to accu-
rately recapitulate the complex nature of
native tissue structures and the biochemi-
cal pathways that accompany such architec-
ture, therefore justifying the use of animal
models.[3–6] Animal models clearly demon-
strate complex tissue structures and path-
ways, although these models have accom-
panying high costs, contentious ethical con-
siderations, and results that do not always
translate across species.[7,8] As such, there
is a growing need for more complex in vitro
models, which provide more representative
structures and physiology than conventional cell cultures, with-
out the complexities of animal research.
Development of increasingly relevant models has shown the
potential of 3D tissue-engineered (TE) solutions for in vitro pre-
clinical testing.[2,9–12] Engineered constructs require a cell source
capable of forming the structures and processes associated with
in vivo tissues. This is in addition to environmental conditions,
such as a substrate/scaffold and specific nutrients, which enable
the establishment of these characteristics. However, due to the
very different physical structures of each of these tissues and
hence their culture conditions, in vitro 3D models of skeletal
muscle and bone have yet to be cultured together.
Myogenic differentiation in both monolayer and 3D requires
muscle progenitor cells (MPCs), or myoblasts, to exit the cell cy-
cle. In vitro, this is generally met through a reduction in serum
content to induce cellular fusion.[13–17] Current 3D muscle mod-
els use this process in tandem with a scaffold to act as an ex-
tracellular matrix. This is typically a cell-seeded hydrogel, which
is tethered during the setting of the hydrogel or during the cul-
ture, as MPCs delaminate and self-assemble between the anchor
points.[18–25] MPCs align according to lines of isometric tension,
which are formed through cell-mediated scaffold contraction over
the culture period.[26] This helps to create highly aligned popula-
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tions of myotubes, which better represents in vivo structure than
monolayer cultures.[5]
TE bonemodels also utilize a scaffold and either an osteoblast-
like cell line or a multipotent stem cell, for example a
mesenchymal stem cell, to act as a source of matrix deposition
and remodeling.[27–29] There are many different types of bone
scaffold based on synthetic or naturally derived materials.[30–36]
Individually, each of these scaffold types have disadvantages,
such as reduced cell affinity.[28,37] However, by combining mate-
rials to create a hybrid/composite scaffold, these disadvantages
can be reduced or eradicated to assist in the formation of a more
relevant bone-like model.[38–41] The addition of ascorbic acid, 𝛽-
glycerophosphate, and dexamethasone have been shown to in-
crease RUNX2/CBFa1 expression and matrix production, as well
as the formation of bone mineral in osteoblast/osteoblast-like
cells.[42]
By comparing the effects of reported skeletal muscle and bone
medium compositions on both cell populations in monolayer
and 3D, this work sought to establish conditions conducive to
the co-culture of 3D TE skeletal muscle and bone toward the for-
mation of an in vitro musculoskeletal junction (muscle–tendon–
bone). This would greatly increase the physiological relevance of
in vitro toxicology testing before in vivo studies and could aid in
the understanding of musculoskeletal diseases.
2. Experimental Section
2.1. Cell Culture
Cell populationswere cultured under humidified atmospheric O2
and 5% CO2 conditions at 37 °C (5% CO2 in air). Medium com-
positions were based upon previous literature (Table 1).[16,43–46]
C2C12 murine MPCs (ECACC, UK) were expanded in M1. All
experiments were conducted prior to passage 8. TE85 human os-
teosarcoma (hOS) cells (ATCC, UK), were expanded in M2, or
growth medium (GM) as detailed for C2C12s (M1). All experi-
ments were conducted prior to passage 60.
2.2. Media Composition Culture Comparisons
2.2.1. Proliferation Phase
Both cell lines were seeded at 4500 cells cm–2 in six-well plates
and cultured for 4 days in M1, M2, or M3. Cells were lysed
and processed for DNA and protein analysis at 24, 48, and 96
h postseeding. Metabolic activity was measured at 96 h, and then
samples were passaged for live cell number and membrane in-
tegrity (viability). Brightfield micrographs were taken using a Le-
ica DMIL LED light microscope prior to lysis for morphological
analysis.
2.2.2. Differentiation Phase
Based on results of the proliferation phase cell culture, a single
maintenance medium (M1) was chosen to culture the cells prior
to differentiating. Cells were cultured as detailed during the pro-
liferation phase. Once confluent, cells were cultured in either os-
teogenic or myogenic differentiation media for 3 days. M2 was
Table 1.Medium compositions.
Growth medium designation Components
M1—Skeletal muscle
precursor maintenance
medium
− Dulbecco’s modified Eagle media
(DMEM)—High glucose (Hyclone)
− 20% Fetal bovine serum (FBS) (PAN Biotech)
− 1% Penicillin/streptomycin (PS) (10 000U
mL–1 and 10 000 µg mL–1; Gibco)
M2—Human osteosarcoma
maintenance medium
− Eagle’s minimum essential medium
(EMEM)–Earle’s balanced salt solution
(EBSS) (Sigma)
− 10% FBS
− 1% l-Glutamine (200 mm; Sigma)
− 1% Non-essential amino acids (NEAA)
(100×; Sigma)
− 1% PS
M3—Osteoblast-like cell
maintenance medium
− DMEM—low glucose (Sigma)
− 10% FBS
− 1% PS
MM—Myogenic medium − DMEM (high glucose)
− 2% Horse serum
− 1% PS
OM—Osteogenic medium − DMEM (low glucose)
− 10% FBS
− 0.1 µm Dexamethasone (Sigma)
− 0.05 mm Ascorbic acid (Sigma)
− 10 mm 𝛽-Glycerol-phosphate (Sigma)
− 1% l-Glutamine
− 1% PS
used as a control for the TE85s. Cells were lysed for analysis at
24, 48, and 72 h postseeding.
2.3. Indirect Contact Co-culture of C2C12 MPCs and TE85 hOS
Polydimethylsiloxane (PDMS, Sylgard 184 Elastomer) was pre-
set in six-well plates (Nunc) and cut to provide a central barrier
approximately 0.5 × 3.5 × 0.5 mm across the wells (Figure 1).
C2C12 MPCs and TE85 hOS cells were seeded separately at 4500
cells cm–2 in 2.0 mL of GM (M1) either side of the barrier and left
to attach for 2 h. GM (M1) was added to each well until the levels
rose above the PDMS (ca. 6.0 mL) and 2.0 mL replenished daily.
At confluency (ca. 72 h postseeding), GM was removed and re-
placed with 1.0 mL myogenic medium (MM) and 0.32 mg mL–1
hydroxyapatite (HA) in MM to the C2C12s and TE85s, respec-
tively. Cultures were left for 2 h at 37 °C/5% CO2 in air to allow
the HA to settle onto the TE85s. MM was then gently added to
the well on top of the boundary to increase levels above the PDMS
barrier (ca. 6.0mL). Cells were lysed for analysis after 3 days. Con-
trols of MPC/hOS –HA, hOS –HA/hOS –HA,MPC/MPC, hOS
+HA/hOS+HA, andMPC/MPCwithHA conditionedmedium
were set up simultaneously.
2.4. TE 3D Collagen Constructs
2.4.1. Skeletal Muscle Model
Skeletal muscle constructs were prepared according to an ad-
justed protocol.[5,16] Briefly, 10× minimal essential medium
(MEM) (Gibco) was added to 2.0 mg mL–1 type-1 rat tail collagen
Biotechnol. J. 2019, 1900106 1900106 (2 of 13) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
Figure 1. Monolayer co-culture systems. Each cell type was separated by a PDMS boundary with secreted and degradation products shared within the
medium. Both cell types exposed to a single medium by filling the well to a volume above the height of the boundary.
Figure 2. Schematic of 3D tissue-engineered co-culture system. (Left) To create the bone construct setting area, the threaded section of a 15-mL cen-
trifuge tube was removed and placed on a PDMS-coated well. The ring was then sealed to the PDMS with 2.0 mg mL–1 collagen. A minutien pin was
placed in the center of the ring to act as an anchor point for the bone construct. A PDMS boundary was placed adjacent to the ring and sealed with
collagen. Not to scale. (Right) 3D skeletal muscle and bone constructs after 14 days culture. Scale bar = 5 mm.
(First Link, UK) and mixed thoroughly. This solution was then
neutralized using 5 m and 1 m NaOH until a color change from
yellow to pink was observed. MPCs suspended in GM (M1) were
then added to the collagen solution and pipetted into a defined
setting area (15 mm x 28 mm) with bespoke anchor points,
termed “A-frames” at either end (Figure 2). The final solution
comprised 85% collagen, 10% 10× MEM, and 5% cell suspen-
sion. Each A-frame consists of poly(ethelene-co-1-octene) plas-
tic 10 count canvas mesh (Darice) bound together with 0.3 mm
stainless steel wire (Scientific Wire Company, UK) to form a
floatation bar. Note that 0.3 mm wire was used to create a hook,
which could be pushed into the floatation bar and hung over the
side of the setting chamber to keep the construct stable.
2.4.2. Bone Model
HA solution and collagen/HA 3D constructs were prepared ac-
cording to an adjusted protocol.[47]
Hydroxyapatite solution preparation: Note that 500 mL of
130 mm analytical grade ammonium phosphate tribasic trihy-
drate (NBS Biologicals Ltd) was added dropwise into 500 mL of
210 mm calcium acetate solution. The solution was continuously
stirred and maintained at pH12 and 3 °C by adding concentrated
ammonium hydroxide and housing in a bath of iced water. The
precipitate solution was then placed into a refrigerator at 4 °C
and left to age overnight. During the aging process, the precipi-
tate settles creating a clear phase separation. The HA precipitate
was washed periodically in dH2O while in storage to retain phase
separation. Samples of the HA suspension were then aliquoted
into 50 mL tubes (FisherBrand) and centrifuged at 4000 rpm for
5 min. The clear phase was removed and replaced with dH2O.
After resuspension in dH2O, 3.7% hydrochloric acid (HCl) was
added to adjust the pH to 7.5, followed by a final wash in dH2O.
Once neutralized, the centrifugation process was repeated until
unbound water was negligible, creating a concentratedHA paste.
The concentration of HA in the paste was measured by calculat-
ing the dry mass as a percentage of the initial sample mass. The
dry mass was obtained by measuring a sample after baking at
80 °C for 30 min.
Bone collagen/hydroxyapatite model: HA was added to 2.0 mg
mL–1 type-1 rat tail collagen in 0.1 m acetic acid (First Link,
UK) to the required concentration and mixed thoroughly. 10×
MEM (Gibco) was added to this mixture and then neutralized
using 5 m and 1 m NaOH until a color change from yellow to
pink was observed. TE85 hOS cells suspended in M1 were then
added to the collagen solution and pipetted into a bespoke plastic
O-ring (ca. 16 mm internal diameter). The final solution com-
prised 85% collagen/HA solution, 10% 10× MEM, and 5% cell
suspension.
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Table 2. Quantitative reverse transcription PCR (qRT-PCR) primers.
Target mRNA (M—mouse;
H—human)
Primer sequences 5′–3′ Reference sequence
accession number
Forward Reverse
POLR2B (M) GGTCAGAAGGGAACTTGTGGTAT GCATCATTAAATGGAGTAGCGTC NM_153798.2
POLR2B (H) AAGGCTTGGTTAGACAACAG TATCGTGGCGGTTCTTCA NM_000938.1
Myogenin (M) CCAACTGAGATTGTCTGTC GGTGTTAGCCTTATGTGAAT NM_031189.2
RUNX2/CBFa1 (H/M) GCAGTATTTACAACAGAGGG TCCCAAAAGAAGTTTTGCTG NM_001145920
Osteocalcin/BGLAP(H) CTCACACTCCTCGCCCTATT TCCCAGCCATTGATACAGGT NM_199173
2.5. Co-culture Platform for 3D TE Skeletal Muscle and Bone
Constructs
3D co-culture molds were created using Nunc Rectangular 8-well
plates coated with PDMS. An area large enough to allow for the
setting of the skeletal muscle construct and placement of the
boundary was cut away from the PDMS covering the well, and
a bespoke plastic O-ring was placed onto the remaining PDMS
covering the well. Note that 2.0 mg mL–1 collagen was used to
seal the resulting ring to the PDMS creating a well to set the bone
construct in. A minutien pin was placed at the center to act as an
anchor point for the bone construct. A separate PDMS boundary
was used to create the setting area for the skeletal muscle con-
struct and sealed using 2.0 mg mL–1 collagen (Figure 2).
Once the skeletal muscle and collagen/cell solutions were
pipetted into the setting areas, the chamber was placed into a
37 °C humidified incubator and left until the collagen mixtures
were fully polymerized. Once set, the construct was detached
from the walls of the setting area, the PDMS and O-ring bound-
ary wall were removed, and M1 was added to the well, allowing
the construct to float. Constructs were cultured for 4 days in M1,
ensuring complete replacement of the medium twice daily. To
induce cellular fusion, constructs were then cultured in MM for
a further 10 days, ensuring complete replacement of MM every
24 h.
2.6. Cyto- and Histochemistry
Fluorescent cell staining was performed as follows. Numbers in
brackets represent timings used when working with 3D collagen
scaffolds to enable liquid penetration through the matrix.
Following culture, the cells were washed twice with phosphate-
buffered saline (PBS) and fixed by the dropwise addition of
methanol and acetone (1:1 v/v) to PBS (50% v/v). This was re-
moved after 15 (30) min incubation, and neat methanol and ace-
tone (1:1 v/v) was added for a further 15 (30)min prior to staining.
Once fixed, cultures were stained for the muscle-specific cy-
toskeletal intermediate filament desmin. Initially constructs were
placed into a blocking solution consisting of 5% goat serum
and 0.2% Triton X-100 in Tris-buffered saline (TBS) for 30 min
(2 h) and then incubated with rabbit anti-desmin antibody
(Abcam, UK) for 2 h (overnight) diluted 1:200 in 2% goat
serum/TBS. The cells were then incubated in the dark for a
further 2 h in goat anti-rabbit IgG rhodamine-derived tetram-
ethylrhodamine (TRITC) or Chromeo 488 conjugated secondary
antibody (Abcam) diluted 1:200 in TBS. For indirect contact
monolayer cultures, phalloidin conjugated with the fluorescent
dye rhodamine was used to visualize cytoskeletal F-actin (Life
Technologies). Samples were incubated in a 1:200 solution of rho-
damine phalloidin with 0.1% Triton-X in PBS for 30 min.
DAPI was used as a counterstain to observe cell nuclei. Sam-
ples were incubated in a 1:10 000 dilution (1 mg mL–1; Thermo
Scientific Pierce) in dH2O for 15 (30)min in the dark before being
washed at least five times in dH2O. All samples weremounted on
glass microscope slides using Fluoromount Aqueous Mounting
Medium (Sigma) and imaged using a LeicaDM2500 fluorescence
microscope with associated software.
2.7. RNA Extraction and Quantitative RT-PCR
Monolayer samples used for quantitative RT-PCR (qRT-PCR)
analysis were first lysed in 500 µL TRI-reagent (Fisher). 3D cul-
tures were placed into 500 µL TRI reagent and snap frozen in liq-
uid nitrogen. Samples were then stored at –80 °C for later RNA
extraction.
Prior to RNA extraction, samples were thawed at room tem-
perature. A steel ball bearing was added to 3D construct sam-
ples and then agitated on a TissueLyser II (Qiagen) for 4 min
at 10 000 rpm to ensure homogenization and cell lysis. RNA
was extracted using TRI-Reagent (Sigma) according to manu-
facturer’s guidelines. qRT-PCR reactions were performed us-
ing QuantiFast SYBR Green RT-PCR kit (Qiagen) and primers
(Table 2) with cycling as follows: 50 °C for 10 min (reverse tran-
scription/cDNA synthesis), 95 °C for 5 min (transcriptase in-
activation and initial denaturation step) followed by PCR steps
for 40 cycles; 95 °C for 10 s (denaturation), 60 °C for 30 s (an-
nealing and elongation). Finally, a dissociation/melt curve anal-
ysis was performed to allow exclusion of nonspecific amplifi-
cation or primer–dimer interference. Relative gene expression
was calculated using ΔΔCT equation[48] where relative expres-
sion is calculated as 2−ΔΔCT (fold change). Each individual sample
was assessed in triplicate and normalized to a single designated
POLR2B reference gene.
2.8. Alkaline Phosphatase Activity, DNA, and Protein
Quantification
Monolayer samples taken for alkaline phosphatase (ALP), DNA,
and protein analysis were lysed in dH2O and taken through three
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freeze-thaw cycles. 3D TE samples were snap frozen with 500 µL
of dH2O in liquid nitrogen. Samples were stored at –80 °C for
later use. A steel ball bearing was added to 3D construct sam-
ples and then agitated on a TissueLyser II (Qiagen) for 4 min at
10 000 rpm. For studies not involving direct contact with HA,
DNA content was measured using a NanoDrop 2000 spectropho-
tometer at 260 nm (Thermo Scientific). For studies involving di-
rect contact withHA, commercially availableQuant-iT PicoGreen
dsDNA Kits (Invitrogen) were used according to manufacturer’s
guidelines.
ALP was measured using a 4-methylumbelliferyl phosphate
(MUP) dephosphorylation assay in which 50 µL of the cell/lysis
buffer solution was placed into a 96-well plate with 50 µL of
dH2O. To this, 50 µL of 4-MUP was added and left for 30 min.
To stop the reaction, 50 µl of 100 mm EDTA buffer was added.
Absorbance readings taken using a Varioskan Flash (ThermoSci-
entific) at 440 nm. Results were compared with a standard curve
of 4-MU. ALPwas normalized toDNA for later construct configu-
ration comparison. Protein concentrations were measured using
a NanoDrop 2000 spectrophotometer at 280 nm.[49]
2.9. Metabolic Activity per Live Cell and Membrane Integrity
Measurements
Metabolic activity was measured using a 10% (v/v) solution of
PrestoBlue (Invitrogen) in the respective GM. Cells were incu-
bated for 30 min in culture conditions and then 100 µL sampled
and read at 544 nm/590 mn (excitation/emission) using a Var-
ioskan Flash. Following trypsinization, membrane integrity (vi-
ability) and live cell numbers were measured using an Acridine
Orange (30 µg mL–1)/DAPI (100 µg mL–1) solution and image
analysis on Nucleocounter NC-3000 (Chemometec).
2.10. Myotube Characteristics
Mean number ofmyotubes, fusion index (percentage of nuclei at-
tributed to myotubes), and mean number of nuclei per myotube
were measured manually from fluorescent images using ImageJ
(NIH).
2.11. Statistics
All data are presented as mean ± standard deviation. To
determine if statistical differences existed between different
medium compositions or indirect co-cultures, analyses of vari-
ance (ANOVA) were performed with a Bonferroni post hoc test.
The results of the 3D TE co-cultures were analyzed using a two-
tailed t-test. All statistical analyses were conducted using Graph-
Pad Prism 5.0.
3. Results
3.1. Medium Composition Culture Comparisons
To create a system in which the major musculoskeletal com-
ponents of skeletal muscle and bone can be co-cultured in
3D, a medium must first be identified that can sustain the
growth and differentiation of both cell types. Three prolifera-
tion phase media were tested, followed by differentiation phase
analysis using a myogenic and an osteogenic medium (Table 1).
DNA concentration changes were used as an indicator of pop-
ulation change and protein/DNA ratios as an indicator of cell
size.
3.1.1. Proliferation Phase
After 48 h, both C2C12 and TE85 DNA and protein
(Figure 3A–D) concentrations increased without any signifi-
cant differences occurring between the three growth media.
After 96 h, C2C12s grown in M1 (C2C12 control medium)
had significantly greater DNA and protein concentrations than
those cultured in M2 and M3 (p ≤ 0.001), demonstrating greater
proliferation in this control media. Contrastingly, TE85s cultured
in M2 (TE85 control medium) had significantly greater DNA and
protein concentrations than either M1 or M3 at 96 h (p ≤ 0.001).
TE85s cultured in M3 exhibited reduced concentrations of DNA
and protein compared to both M1 and M2, respectively; there-
fore, to achieve a consistent proliferation timeline comparative
to previous cultures and models, M3 would be unsuitable for co-
culture. These trends can also be observed in brightfield images
(Figure S1, Supporting Information) with increasing coverage
to full confluency for all conditions after 96 h, except for TE85s
cultured in M3, which show large areas of uncovered surface.
Protein/DNA (Figure 3E,F) ratios indicate changes in cellular
population morphology. After 96 h, no significant differences oc-
cur between M1, M2, or M3 conditions in both C2C12 and TE85
cultures.
These data indicate that each medium condition produced
only a proliferative effect rather than additional changes in cell
size (hyperplasia rather than hypo- or hypertrophy), although
a numerical bias toward the control media was observed. This
bias was more pronounced without a preconditioning step,
where changes in basal medium (from DMEM to EMEM or
EMEM to DMEM) resulted in significantly less (p < 0.001) DNA
concentrations at 96 h after seeding (Figure S1, Supporting
Information).
Additionally, for C2C12s cultured inM1, metabolic activity per
live cell (MAC) was slightly greater, although not statistically sig-
nificant (Figure 3G,H). Conversely, for TE85s, M1 cultures exhib-
ited a slightly lower nonsignificant MAC, potentially reflecting
the lower 96-h DNA profile than M2 culture despite nonsignifi-
cance after 48 h.Membrane integrity (Figure 3 I,J), following pas-
sage at 96 h, was not significantly different in C2C12s (ca. 93%).
In TE85 M1 cultures, membrane integrity was statistically sig-
nificantly lower, although this difference is considered negligible
(ca.96.0 ± 1.0% vs ca.98.0 ± 0.4%).
Although TE85s cultured in M2 demonstrated significantly
greater DNA concentrations after 96 h, TE85 M1 cultures
were still able to reach full confluency, while M2 affected
C2C12 cultures to a greater extent than M1 (C2C12 control
medium), possibly due to the reduced serum (20% in M1,
10% in M2). Following this, M1 was chosen as a proliferation
medium for subsequent medium composition and co-culture
experiments.
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Figure 3. C2C12 and TE85 growth medium composition comparisons. DNA (A, B) and protein concentrations (C, D). E, F) Protein/DNA ratios. G, H)
96-h Metabolic activity/live cell number. I, J) 96-h Viability (membrane integrity). n = 3 per time point per condition + 3 replicates per well. *p < 0.05,
**p < 0.01, ***p < 0.001.
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Figure 4. A–F, P–S) C2C12 and TE85 (G–O, T–V) differentiation medium composition comparisons. A–F) Monolayer C2C12 morphological observation:
desmin (red) and DAPi (blue). Unfused nuclei show little or no presence of desmin (denoted by→). G–O) Brightfield images of TE85 human osteosar-
coma cells after culture to confluency in M1 and then exposure to either myogenic or osteogenic medium (M2 + osteogenic medium control). P) DNA
concentrations in C2C12 cultures. Q) Protein/DNA ratios. Real-time qRT-PCR (2−ΔΔCT) profiles of myogenic and osteogenic markers. R) Myogenin
expression and (S) RUNX2/CBF-𝛼1 expression of C2C12 cells in myogenic and osteogenic medium. TE85 culture’s after 3 days (T) DNA concentrations
and (U) protein/DNA ratios. V) RUNX2/CBF-𝛼1 expression of TE85 cultures in myogenic and osteogenic. Scale bar = 50 µm; n = 3 culture replicates +
3 repeat measures for all conditions. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
3.1.2. Differentiation Phase
Fluorescent microscopy shows C2C12s cultured in MM have
successfully formed myotubes and become increasingly hy-
pertrophic at 72 h, with some unassociated nuclei present
(Figure 4A–F). Corresponding DNA concentrations did not sig-
nificantly change over the 72-h differentiation period, indicat-
ing exit from the cell cycle. This is accompanied by a significant
(p< 0.01) increase in protein/DNA ratios after 48 h (Figure 4P,Q).
C2C12s in osteogenic medium (OM) experienced a significant
Biotechnol. J. 2019, 1900106 1900106 (7 of 13) © 2019 The Authors. Biotechnology Journal published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
www.advancedsciencenews.com www.biotechnology-journal.com
reduction (p< 0.0001) inDNA concentrations after 48 h. This was
without an accompanying change in protein/DNA ratios, indicat-
ing a loss in cell number, possibly due to detachment through
overconfluence. However, these cultures still had greater DNA
concentrations than C2C12s (MM) after 72 h. C2C12s in OM also
experienced a reduction in desmin presence over the culture pe-
riod, indicating a probable loss of myogenic potential.
TE85 cultures in OM show a greater concentration (p < 0.05)
of DNA after 24 h in comparison to MM, although only M2+OM
(TE85 control medium) had significantly greater DNA after 72 h
(p < 0.05). Brightfield micrographs support this with an observ-
able increase in cell density over time inOMcultures (Figure 4H–
N and I–O) without cell size changes occurring (due to potentially
harmful factors such as aging) as indicated by protein/DNA ra-
tios not varying significantly over time (Figure 4T–U).
qRT-PCR results of C2C12 myogenin expression (Figure 4R)
showed an increase over 72 h in MM, with no changes evident
within OM. To confirm no osteogenic effects within the C2C12
population, RUNX2 expression was also assessed (Figure 4S) and
no significant changes were observed. RUNX2 expression within
TE85 cultures increased significantly in all cultures (Figure 4V).
Fluorescent imaging in TE85 cultures showed no desmin pres-
ence across all cultures indicating no lineage altering effects of
MM (Figure S2, Supporting Information).
With a reduction in desmin presence and no myogenic fu-
sion, in addition to the lack of change in myogenin expression
in C2C12 OM cultures as well as an increase in RUNX2 in TE85
MM cultures, M1 followed by MM has demonstrated a suitabil-
ity to enable the development of a skeletal muscle and bone co-
culture system.
3.2. Effects of Indirect Contact of Skeletal Muscle and Bone
in Monolayer Cultures
As a monolayer representation of 3D skeletal muscle and bone
cultures, monolayer cultures of C2C12 and TE85/HA were co-
cultured in the same well but separated by a PDMS boundary.
This was to understand the effects of TE85 and C2C12 intercel-
lular interactions, such as paracrine signaling, and contact with
HA.
Unlike the C2C12 fusion to formmyotubes, TE85s do not visi-
bly differentiate. To differentiate, cellsmust first exit the cell cycle,
so to assess changes in TE85 cell growth, DNA concentrations
were measured after direct/no exposure to HA and with/without
C2C12s cultured in the adjacent chamber. TE85s co-culturedwith
C2C12s in the absence of HA had significantly greater DNA con-
centrations than all other conditions (Figure 5A). This indicates
that the addition of secreted factors from the C2C12s is influenc-
ing the growth of the TE85s in co-culture. These factors would
not be present in TE85 only cultures and the influence may be
reduced by the presence of HA in the TE85/C2C12 + HA cul-
tures. ALP concentrations of TE85 cultures normalized to DNA
(Figure 5B) shows that the addition of C2C12 and HA does not
inhibit production of ALP relative to TE85 only controls and is
significantly greater (p ≤ 0.05) than C2C12/TE85 – HA cultures.
Immunofluorescence of C2C12 cultures (Figure 5C–F)
shows evidence of myogenic fusion in all cultures, although
C2C12/TE85 + HA cultures appear to show reduced myotube
formation. Desmin is still present in the nonfused cells. Image
analysis (Figure 5G–I) confirms that fusion is limited in C2C12s
with both the presence of TE85s and HA, although not in HA
conditioned medium. This suggests that TE85s paracrine and
secreted factors reduce the fusion capability of C2C12s in the
culture timeframe, the effect of which is enhanced with an
interaction with HA.
3.3. Co-culture of TE 3D Skeletal Muscle and Bone Constructs
Prior to the creation of a musculoskeletal junction, conditions
amenable to the successful co-culture of skeletalmuscle and bone
must first be understood. 3D skeletal muscle and bone cultures
were set up and cultured in the same well. After 14 days culture
(4 days M1, 10 days MM), samples were taken to analyze mark-
ers of differentiation. RUNX2/CBFa1 mRNA expression was in-
duced nearly 150-fold (p < 0.05) in bone constructs co-cultured
alongside engineered skeletal muscle in comparison to bone
constructs cultured in isolation in the same media conditions
(Figure 6A). Osteocalcin/BGLAP (Figure 6B) was also found to
be more highly expressed (p ≤ 0.05) in co-cultures. ALP concen-
tration was not significantly different between cultures, although
co-culture levels tended to be lower (Figure 6C). These results in-
dicate that co-culture bone cell populations exhibit a greater os-
teogenic potential than control cultures, and also demonstrates
that C2C12s positively interact with TE85 cultures in 3D. The
presence of HA in the scaffold precluded the use of common
stains, such as Alizarin Red, and obscures observation of the cells
through brightfield microscopy, as such further analysis through
microscopy could not be obtained.
Cellular fusion was observed in all constructs (Figure 6D–F),
although in the co-cultured skeletal muscle construct there were
large numbers of unfused cells and the existing myotubes were
not as hypertrophic as those in the skeletal muscle constructs cul-
tured in isolation. Mean maximum myotube length per image
reflects this with skeletal muscle only cultures, demonstrating a
significantly greater (p ≤ 0.05) mean maximum length, although
the mean length for both skeletal muscle only and co-cultures
were not significantly different. However, the average number of
myotubes per image was substantially reduced in co-culture con-
structs (p< 0.001). This demonstrates a continuation of the nega-
tive effects shown in monolayer cultures in the reduction during
myotube formation.
4. Discussion
Successful development of a skeletal muscle and bone co-culture,
which replicates key characteristics of in vivo tissue, would be of
great benefit to in vitro investigations into the musculoskeletal
system and could enable the progress toward the generation of
a full in vitro musculoskeletal junction (muscle–tendon–bone).
Progression of such a culture systemwith standardizedmanufac-
turing parameters, such as those proposed by Wragg,[50,51] could
also reduce the reliance on animal models in preclinical studies,
while also allowing for the testing of efficacy and toxicity of de-
velopmental pharmaceuticals, biomaterials, and medical devices
in a more biomimetic environment. In the present study, the
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Figure 5. Monolayer co-culture differentiation: TE85 cell population DNA quantification and ALP/DNA ratio after 7 days culture (4 days in growth
medium + 3 days in differentiation medium). A) DNA concentrations. B) ALP/DNA ratios. Immunofluorescent images of (C) C2C12, (D) C2C12 + HA
conditioned media, (E) C2C12/TE85 – HA, and (F) C2C12/TE85 + HA. Blue = nuclei (DAPI); red = F-actin (rhodamine phalloidin); green = desmin
(Chromeo 488). Scale bar = 20 µm. G) Mean number of myotubes per image. H) Fusion index per image. I) Mean nuclei per myotube per image. n = 3
replicate cultures + 3 repeat measures. *p < 0.05, **p < 0.01, ***p < 0.001, bars represent ±SD.
variables required to facilitate co-culture of both the C2C12 myo-
genic and TE85 osteogenic cell lines have been established, cul-
minating in successful growth and differentiation of skeletal
muscle and bone 3D tissues in vitro.
As one of themajor factors affectingmyoblast fusion and bone
matrix secretion, investigating the effects of different medium
composition on proliferation and differentiation is of high impor-
tance. While co-culture systems described within the literature
report the influence of one cell type on the other, these papers
have yet to describe the conditions which allow for the successful
culture and differentiation of both cell types in a single medium
system through experimental comparisons.[52–55]
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Figure 6. 3D skeletal muscle and bone co-culture: Real-time qRT-PCR (2−ΔΔCT) measurement of RUNX2/CBF-𝛼1 (A), osteocalcin/BGLAP (B), and
ALP/DNA ratios (C) in co-culture and bone model only controls. Immunofluorescence of (D) skeletal muscle only constructs myotubes, (E) aligned
myotubes within a skeletal muscle construct co-cultured with bone constructs (fluorescence interference from collagen matrix), and (F) fused and
unfused C2C12s within a skeletal muscle construct co-cultured with bone constructs. Blue = nuclei; red = desmin. Scale bar = 100 µm. Image analysis
of myotube characteristics: G) Maximum myotube length. H) Mean myotube length. I) Number of myotubes per image. n = 4 repeat conditions + 3
repeat measures. *p ≤ 0. 05, ***p < 0.001, bars represent ±SD.
In the experiments reported herein, a restriction in the con-
centrations of glucose between medium significantly negatively
affected the C2C12 line and was not offset by the addition of
glutamine.[56–58] A deficit in the fetal bovine serum (FBS) sup-
plement concentration was also implicated in the restriction
of population growth of the myogenic cells. Myogenic cell lin-
eages are typically cultured in a high-glucose (4500 mg L–1) basal
medium with at least 10% FBS, although 20% FBS supplemen-
tation has been shown to produce more favorable results.[59–63]
Conversely, the TE85 cell line showed greater proliferation with
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a lower glutamine, glucose, and FBS concentrations. Osteogenic
cell lineages are typically cultured in low-glucose (1000 mg L–1)
medium with 10% FBS and an addition of nonessential amino
acids.[64–68] Regardless of these outcomes, both skeletal muscle
and osteoblast-like cell types show a capacity for proliferation
in all media with a bias toward each cell type’s typical culture
medium as expected. However, C2C12s were affected to a greater
extent than TE85s, resulting in high-glucose DMEM + 20% FBS
being chosen as a suitable proliferation medium for both cell
lines.
Myogenic cells have also shown the ability to differentiate
along an osteoblastic lineage and conditions promoted through
blast and crush injury demonstrate this capacity in vivo.[59,69–72]
As a marker for osteoblast progression, RUNX2 has been estab-
lished as the initial trigger of the osteogenic cascade, resulting in
ALP production and an upregulation of BGLAP/osteocalcin. Un-
der culture with common osteogenic supplements (𝛽-glycerol-
phosphate, ascorbic acid, and dexamethasone), C2C12s showed
no change in myogenin expression across 3 days and no sig-
nificant differences in RUNX2 expression. This is in compar-
ison to the classic upregulation followed by subsequent de-
crease in myogenin expression observed in MM serum-starved
cultures.[42,73–75] Under reduced serum conditions (MM), C2C12s
fused to form smallmyotubes dispersed between desmin positive
cells, which later progressed to form multiple hypertrophic my-
otubes, in line with classic in vitro skeletal muscle culture. How-
ever, C2C12s cultured in OM demonstrated a decrease in desmin
presence with an increase in nondesmin-associated nuclei and
punctate staining. The low-glucose aspect of the OM potentially
caused a reduction inmetabolic activity, accompanied by the pres-
ence of dexamethasone, a known inducer of atrophy[76–78] and
other osteogenic factors may have caused a reversion to a more
progenitor-like state, alluded to in skeletal muscle calcification
conditions.[69] A lack of RUNX2/Cbfa1 upregulation supports a
reversion theory to a less committed cell type, rather than a direct
lineage change as in the case of BMP-2 stimulated culture.[59]
Much like the skeletal MPCs, osteoblasts exit the cell cy-
cle prior to differentiating.[79,80] Once the TE85 cultures growth
profiles are stabilized, they displayed an upregulation of
RUNX2/Cbfa1 in all cultures after 3 days and nondesmin-
associated nuclei without evidence of cellular fusion. The concen-
tration and the type of serum in the differentiation medium do
not seem to affect the final expression of RUNX2/CBFa1. How-
ever, the osteogenic supplements may reduce the latent time be-
fore expression is upregulated. Therefore, low non-fetal serum
(2% horse serum) could be used in subsequent studies involving
osteoblasts-like cells, which would reduce the costs involved in
cultures of this type.
Once defining the appropriatemedium compatibility protocol,
the influence of each cell type in the same culture environment
was assessed with the addition of HA to stimulate further dif-
ferentiation and mimic part of the composition of in vivo bone
matrix. HA, in this case, was found to inhibit DNA concentra-
tions within TE85 populations in co-culture with C2C12s but in-
crease ALP/DNA in TE85 only and co-culture conditions. TE85s
may have downregulated markers relevant to the production of
ALP and are therefore self-regulating responses once exposed to
HA. This self-regulation has been reported in reference to or-
ganic/inorganic pyrophosphate ratios.[81]
Current monolayer toxicity tests are generally single cell type
and conducted in accordance with ISO10993 for medicinal de-
vices or through high-throughput studies in drug discovery (ISO
Identification ofMedicinal Products). Themonolayer systempre-
sented here, using both skeletal muscle and osteoblast cell lines,
and incorporating elements of ECM to induce osteogenesis, cre-
ates a more relevant system for testing neighborhood effects of
toxicity. The ease of setup would lend itself to high-throughput
techniques in smaller culture wells, although alternatives such
as trans-well inserts should be considered.[82–85] Additionally, this
system could be used to investigate musculoskeletal conditions,
such as the exposure of skeletal muscle to bone cells and ECM
in blast injuries[69] by removal of the central barrier, similar to
Wang et al.,[86] in which mature populations were allowed to mi-
grate and mix when observing enthesis healing.
The final component of the 3D co-culture, the collagen scaf-
fold, allows the cells to reside in three dimensions. Reported
medium protocols do not normally change between monolayer
and 3D work, however, 3D cultures exhibit longer culture peri-
ods before definitive differentiation.[16,23,87] Additionally, consid-
ering the different volumetric shapes and mechanical influences
(anchor points) to which each of the skeletal muscle and bone
construct were developed, a novel co-culture system needed to be
created to allow co-exposure to the medium. Previous co-culture
systems utilized a well-established delamination model, creating
cylindrical 3D constructs and concentrating on biological outputs
without regard to creating individual properties to best support
each tissues formation.[88–90] The platform developed here sought
to enable the formation of each of the constructs as previously de-
scribed, in both shape and cellular differentiation.[5,11,16,50] Sub-
sequent observation of each construct did not demonstrate any
obvious deviation from single construct formation and analy-
sis of differentiation showed enhancement of gene expression
in the bone construct. While fusion in the skeletal muscle con-
structs was diminished, an increased culture period may encour-
age similar myotube characteristics to isolated skeletal muscle
constructs. This diminished myotube fusion in the presence of
HA and TE85s was also observed in the monolayer co-cultures
and indicates continuity in cell behavior between monolayer and
3D platforms. Increasing bone-specific gene expression in the
presence of skeletal muscle, without mechanical loading, is sup-
ported by a growing body of work in the influence of “myokines”
on bone formation.[91–93] The effect of bone on muscle has had
little study, although it has been reported that bone cell culture
secretions impair skeletal muscle formation.[94]
Considering the reported successes in skeletal muscle–tendon
and bone–tendon models,[88,90] as well as tendon formation in a
collagen hydrogel, the addition of a tendon component to this
model should not be considered a prohibitive obstacle to the con-
struction of an in vitro musculoskeletal junction.[95,96] Ultimately,
this strategy can be applied to more physiologically relevant hu-
man stem cell–derived cell types involved in the native muscu-
loskeletal junction in order to achieve a more accurate prediction
of drug testing responses.
In summary, this study represents the first reported instance
of simultaneous 3D TE skeletal muscle and bone differentia-
tion in co-culture, with evidence of an enhancing effect on bone-
specific gene expression. A single GM (high-glucose DMEM
+ 20% FBS) was found to enable proliferation of the C2C12
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muscle precursor and the TE85 osteosarcoma cell lines. This was
coupled with high-glucose DMEM + 2% horse serum to enable
fusion of C2C12s to formmyotubes, an increase in expression of
RUNX2/CBFa1 in TE85 cultures. When inmonolayer co-culture,
both cell types could proliferate and differentiate in the presence
of each other and HA with the chosen medium protocol. 3D co-
culture of skeletal muscle and bone in vitro demonstrated en-
hanced osteogenic gene expression in the bone model, in com-
parison to isolated bone controls, with no significant differences
in ALP activity. Co-cultured skeletal muscle constructs retained a
capacity for myoblast fusion, although this appeared diminished
when compared to controls.
Future work should seek to use the methods described here
to create a 3D tendon construct with a view to attachment to
the bone and skeletal muscle models to form a full in vitro 3D
TE musculoskeletal junction (muscle–tendon–bone). Addition-
ally, the monolayer co-culture model should be further charac-
terized in conjunction with the 3D co-culture to enable a com-
parative platform progression for testing.
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